semaglutide concentration exposure is dose proportionate in the PIONEER and SUSTAIN Physiologically based pharmacokinetic modelling of

Growth hormone-releasing hormone in normal aging: An Update

Dose Group GI Adverse Events (%) Nausea (%) Abdominal Discomfort/Pain Placebo 32.6% 11.6% Low baseline 1 mg 48.6% ~20% Mild, infrequent 4 mg (escalated) 60.0% ~30% Moderate increase 8 mg (escalated) 57.5% ~38% Present in dose-escalation phase 12 mg (escalated) 66.7% 45.8% Highest incidence, mostly transient Source: Jastreboff AM, Kaplan LM, Fras JP, et al

It plays critical roles in fetal vision and nervous system growth and development

The mechanism underlying its therapeutic effects partly correlated to its influence on dynamic methylation/demethylation pathways